Paul Choi
Stock Analyst at Goldman Sachs
(3.79)
# 618
Out of 4,827 analysts
110
Total ratings
56.52%
Success rate
5.58%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $10 → $5 | $2.29 | +118.34% | 10 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Neutral | $12 → $8 | $6.81 | +17.47% | 3 | May 2, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $60 → $52 | $35.54 | +46.31% | 2 | Apr 17, 2025 | |
| VIR Vir Biotechnology | Maintains: Buy | $28 → $21 | $5.41 | +288.17% | 8 | Apr 17, 2025 | |
| URGN UroGen Pharma | Maintains: Neutral | $22 → $16 | $10.67 | +49.95% | 3 | Apr 17, 2025 | |
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $7.15 | +67.83% | 3 | Apr 17, 2025 | |
| GOSS Gossamer Bio | Maintains: Buy | $8 → $7 | $1.12 | +525.00% | 5 | Apr 17, 2025 | |
| ESPR Esperion Therapeutics | Maintains: Neutral | $4 → $3 | $0.89 | +236.02% | 9 | Apr 17, 2025 | |
| DVAX Dynavax Technologies | Maintains: Sell | $12 → $10 | $9.67 | +3.41% | 4 | Apr 17, 2025 | |
| AMRN Amarin Corporation | Maintains: Sell | $20 → $7 | $10.71 | -34.64% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $159.39 | +41.16% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $143 | $80.44 | +77.77% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $42 | $42.51 | -1.20% | 7 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 → $60 | $32.48 | +84.73% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $14.54 | +30.67% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $26.72 | +19.76% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $34.85 | +43.47% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $4.53 | +319.43% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $2 | $0.32 | +526.17% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $0.89 | +2,721.67% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $4 | $0.33 | +1,119.88% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $20.25 | +739.51% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $3.07 | +160.59% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $33 | $29.38 | +12.32% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $112 | $46.20 | +142.42% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $117.52 | +14.87% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $18 → $20 | $0.62 | +3,131.54% | 2 | Mar 30, 2020 |
Phathom Pharmaceuticals
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $2.29
Upside: +118.34%
Arvinas
May 2, 2025
Maintains: Neutral
Price Target: $12 → $8
Current: $6.81
Upside: +17.47%
Xenon Pharmaceuticals
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $35.54
Upside: +46.31%
Vir Biotechnology
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $5.41
Upside: +288.17%
UroGen Pharma
Apr 17, 2025
Maintains: Neutral
Price Target: $22 → $16
Current: $10.67
Upside: +49.95%
REGENXBIO
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $7.15
Upside: +67.83%
Gossamer Bio
Apr 17, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $1.12
Upside: +525.00%
Esperion Therapeutics
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $0.89
Upside: +236.02%
Dynavax Technologies
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $9.67
Upside: +3.41%
Amarin Corporation
Apr 17, 2025
Maintains: Sell
Price Target: $20 → $7
Current: $10.71
Upside: -34.64%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $159.39
Upside: +41.16%
Dec 18, 2024
Initiates: Buy
Price Target: $143
Current: $80.44
Upside: +77.77%
Dec 4, 2024
Maintains: Sell
Price Target: $32 → $42
Current: $42.51
Upside: -1.20%
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $32.48
Upside: +84.73%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $14.54
Upside: +30.67%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $26.72
Upside: +19.76%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $34.85
Upside: +43.47%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $4.53
Upside: +319.43%
Jun 27, 2023
Maintains: Sell
Price Target: $16 → $2
Current: $0.32
Upside: +526.17%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $0.89
Upside: +2,721.67%
May 24, 2022
Maintains: Neutral
Price Target: $10 → $4
Current: $0.33
Upside: +1,119.88%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $20.25
Upside: +739.51%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $3.07
Upside: +160.59%
Mar 22, 2021
Assumes: Buy
Price Target: $33
Current: $29.38
Upside: +12.32%
Mar 22, 2021
Assumes: Buy
Price Target: $112
Current: $46.20
Upside: +142.42%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $117.52
Upside: +14.87%
Mar 30, 2020
Upgrades: Neutral
Price Target: $18 → $20
Current: $0.62
Upside: +3,131.54%